WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary. “Dr.
How to make the most of partnering at BIO 2026. Plus our explainer on PDUFA. (719 words, 2 minutes, 53 seconds) Experts break down strategies for business development at BIO 2026 Experts explained how ...
At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...
At the 2026 BIO International Convention, we come together Driven by Purpose to forge meaningful connections and advance innovations that improve lives. Successful partnering starts with a clear ...
As monoclonal antibody (mAb) programs approach IND, delays often stem from fragmented development, tech transfer complexity, and limited process efficiency. In this webinar, Thermo Fisher Scientific ...
BIO last week launched the “Fight of Our Lives,” a campaign sharing stories of the people who tackle health challenges every day and underscoring the urgency of their fight. Why it matters: Over the ...
BIO's Ohio trip spotlights gene therapy hub. Plus biotech innovation in women's health. (854 words, 3 minutes, 25 seconds) BIO on the American Road visits Columbus gene therapy hub The gene therapy ...
Americans want healthcare reforms that directly lower out-of-pocket costs while protecting the U.S. biotech industry and the numerous cutting-edge medicines, millions of jobs, and trillions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results